Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Tumors × camrelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Oligometastatic Gastrointestinal Cancer 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Extensive Stage Small Cell Lung Cancer 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Hepatocellular 1 BRAF V600E-mutated /MSS Metastatic Colorectal Cancer 1 Advanced Tumors 1 Advanced Solid Tumors 1 Advanced Solid Tumor 1 Advanced Gastric Cancer 1 Advanced Cervical Cancer 1

Interventions

toripalimab 1 camrelizumab 1 Radiotherapy 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05799183 2024-12-31

A SHR-1210 BE Study on Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡